JP2023538091A - Ｂｔｋ阻害剤としての複素環式化合物 - Google Patents

Ｂｔｋ阻害剤としての複素環式化合物 Download PDF

Info

Publication number
JP2023538091A
JP2023538091A JP2023512198A JP2023512198A JP2023538091A JP 2023538091 A JP2023538091 A JP 2023538091A JP 2023512198 A JP2023512198 A JP 2023512198A JP 2023512198 A JP2023512198 A JP 2023512198A JP 2023538091 A JP2023538091 A JP 2023538091A
Authority
JP
Japan
Prior art keywords
mmol
alkyl
mixture
compound
esi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023512198A
Other languages
English (en)
Japanese (ja)
Inventor
チェン、シャンヤン
パン、イーチョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Innocare Pharma Tech Co Ltd
Original Assignee
Beijing Innocare Pharma Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Innocare Pharma Tech Co Ltd filed Critical Beijing Innocare Pharma Tech Co Ltd
Publication of JP2023538091A publication Critical patent/JP2023538091A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023512198A 2020-08-20 2021-08-19 Ｂｔｋ阻害剤としての複素環式化合物 Pending JP2023538091A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010836243.4A CN114075190A (zh) 2020-08-20 2020-08-20 杂环类btk抑制剂
CN202010836243.4 2020-08-20
PCT/CN2021/113535 WO2022037649A1 (en) 2020-08-20 2021-08-19 Heterocyclic compounds as btk inhibitors

Publications (1)

Publication Number Publication Date
JP2023538091A true JP2023538091A (ja) 2023-09-06

Family

ID=80282666

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023512198A Pending JP2023538091A (ja) 2020-08-20 2021-08-19 Ｂｔｋ阻害剤としての複素環式化合物
JP2023512197A Active JP7669063B2 (ja) 2020-08-20 2021-08-19 Ｂｔｋ阻害剤としての架橋二環式化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023512197A Active JP7669063B2 (ja) 2020-08-20 2021-08-19 Ｂｔｋ阻害剤としての架橋二環式化合物

Country Status (5)

Country Link
US (1) US20230192691A1 (https=)
EP (1) EP4200283A4 (https=)
JP (2) JP2023538091A (https=)
CN (2) CN114075190A (https=)
WO (2) WO2022037650A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021180107A1 (en) * 2020-03-12 2021-09-16 Fochon Pharmaceuticals, Ltd. Compounds useful as kinase inhibitors
CN114075190A (zh) * 2020-08-20 2022-02-22 北京诺诚健华医药科技有限公司 杂环类btk抑制剂
CN114573586B (zh) * 2020-11-28 2023-11-03 杭州和正医药有限公司 一种抑制布鲁顿酪氨酸激酶活性的多环化合物、药物组合物及其应用
CN114634512B (zh) * 2020-12-16 2023-11-14 江苏恒瑞医药股份有限公司 作为布鲁顿酪氨酸激酶抑制剂的化合物、其制备方法和医药应用
JP2025508964A (ja) * 2022-03-03 2025-04-10 深▲チェン▼市塔吉瑞生物医薬有限公司 シクロアルキルまたはヘテロシクリルで置換されたヘテロアリール化合物、並びにその組成物及び使用
WO2025007863A1 (zh) * 2023-07-03 2025-01-09 深圳市塔吉瑞生物医药有限公司 1H-吡唑并[4,3-c]吡啶化合物及其组合物及用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
WO2015132799A2 (en) * 2014-02-03 2015-09-11 Cadila Healthcare Limited Novel heterocyclic compounds
GB201410430D0 (en) * 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds
WO2016019237A2 (en) * 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016106623A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016106624A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016106652A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
JP7337502B2 (ja) * 2015-09-16 2023-09-04 ロクソ オンコロジー， インコーポレイテッド がんの治療のためのｂｔｋ阻害剤としてのピラゾロピリミジン誘導体
AU2017383236B2 (en) * 2016-12-21 2022-02-10 Acerta Pharma B.V. Imidazopyrazine inhibitors of Bruton's tyrosine kinase
WO2020015735A1 (zh) * 2018-07-20 2020-01-23 正大天晴药业集团股份有限公司 布鲁顿酪氨酸激酶抑制剂
CN110964016B (zh) * 2018-09-29 2021-05-28 南京药捷安康生物科技有限公司 氨基降茨烷衍生物及其制备方法与应用
CN113365631B (zh) * 2019-01-18 2024-08-30 杭州邦顺制药有限公司 布鲁顿酪氨酸激酶抑制剂
WO2021180107A1 (en) * 2020-03-12 2021-09-16 Fochon Pharmaceuticals, Ltd. Compounds useful as kinase inhibitors
AU2020436612A1 (en) * 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
CN114075190A (zh) * 2020-08-20 2022-02-22 北京诺诚健华医药科技有限公司 杂环类btk抑制剂

Also Published As

Publication number Publication date
WO2022037650A1 (en) 2022-02-24
EP4200283A1 (en) 2023-06-28
JP2023538090A (ja) 2023-09-06
CN116670119A (zh) 2023-08-29
CN116670119B (zh) 2026-04-14
EP4200283A4 (en) 2024-10-23
CN114075190A (zh) 2022-02-22
US20230192691A1 (en) 2023-06-22
WO2022037649A1 (en) 2022-02-24
US20230212175A1 (en) 2023-07-06
JP7669063B2 (ja) 2025-04-28

Similar Documents

Publication Publication Date Title
CN113651814B (zh) Kras突变蛋白抑制剂
CA3042960C (en) Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof
JP2023538091A (ja) Ｂｔｋ阻害剤としての複素環式化合物
TWI794232B (zh) 激酶抑制劑及其用途
CN115304623A (zh) 一种嘧啶并环衍生物及其在医药上的应用
CN113795483A (zh) 作为shp2拮抗剂的甲酰胺-嘧啶衍生物
WO2021115457A9 (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
CN118772176A (zh) 一种嘧啶并芳环化合物及其制备方法和用途
KR20220140710A (ko) 트리아졸로피리다진 유도체, 이의 제조 방법, 약물 조성물 및 용도
CN116546985A (zh) 吡啶并嘧啶类衍生物及其制备方法和用途
CN104837844A (zh) 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪
JP2022554385A (ja) Ｗｄｒ５阻害剤及び調節剤
KR20210066839A (ko) Fgfr4 저해제 및 그것의 용도
CN120530110A (zh) 杂环化合物、药物组合物及其应用
US10550125B2 (en) Prodrugs of imidazotriazine compounds as CK2 inhibitors
WO2022127869A1 (zh) 杂环类jak抑制剂
CN112384506B (zh) 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用
HK40042275A (en) Indoline-1-formamide compound, preparation method therefor, and medical use thereof
HK40042275B (en) Indoline-1-formamide compound, preparation method therefor, and medical use thereof
HK40065459A (en) Kras mutant protein inhibitors
HK40051466A (en) Kras mutant protein inhibitors
WO2024212941A1 (zh) Cbl-b抑制剂
HK40052926B (en) Kras mutant protein inhibitors
HK40052926A (en) Kras mutant protein inhibitors
CN115557946A (zh) 杂环内酰胺类化合物，包含其的药物组合物及其用途